Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US10035824B2 · kind B2 · utility
19Cited by
20References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 4, 2017 |
| Grant date | Jul 31, 2018 |
| Priority date | — |
| Expiry date | Dec 4, 2037 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/065
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.